Article Information
History
- November 4, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Tan Hui1,2,
- Lu Liu2,
- Ying Yi3,
- Carmen Valenzuela4,
- Qiang Zhao2,
- Zhiwei Zhang1,
- Wen Li3,*,
- Silvio E. Perea5,* and
- Yasser Perera3,5,*
- 1Cancer Research Institute of Hengyang Medical School, Key Laboratory of Cancer Cellular and Molecular Pathology in Hunan Province, University of South China, 28 Changsheng Road, Hengyang 421001, Hunan Province, China. People’s Republic of China
- 2Department of Pathology, The First Affiliated Hospital of University of South China, Hengyang, 421001, Hunan Province, China. People’s Republic of China
- 3China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Yangjiaqiao Street, Lengshuitan District, Yongzhou City, Hunan Province, 425000, China. People’s Republic of China
- 4Institute of Cybernetics, Mathematics and Physics, Havana, Cuba, Calle 15 entre Cy D. Plaza de la Revolución. CP 10400; La Habana, Cuba
- 5Molecular Oncology Group, Department of Pharmaceuticals, Biomedical Research Division, Center for Genetic Engineering & Biotechnology (CIGB), Havana 10600, Cuba
- ↵*Correspondence: ypereranegrin{at}ccbjic.com (YP); silvio.perea{at}cigb.edu.cu (SEP); liwen{at}ccbjic.com(WL)
Posted November 04, 2024.
Circulating Levels of HMGB-1 and NPM/B23 proteins and Clinical Significance in Debut NSCLC patients
